FDG PET/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of $^{177}$Lu-lilotomab satetraxetan for treatment of relapsed non-Hodgkin lymphoma

Ayca Løndalen 1,2, Johan Blakkisrud 1,3, Mona-Elisabeth Revheim 1,2, Ulf Erik Madsbu 1, Jostein Dahle 4, Arne Kolstad 5, Caroline Stokke 1,3

Abstract
Purpose $^{177}$Lu-lilotomab satetraxetan targets the CD37 antigen and has been investigated in a first-in-human phase 1/2a study for relapsed non-Hodgkin lymphoma (NHL). Tumor dosimetry and response evaluation can be challenging after radioimmunotherapy (RIT). Changes in FDG PET/CT parameters after RIT and correlations with tumor-absorbed doses has not been examined previously in patients with lymphoma. Treatment-induced changes were measured at FDG PET/CT and ceCT to evaluate response at the lesion level after treatment, and correlations with tumor-absorbed doses were investigated.

Methods Forty-five tumors in 16 patients, with different pre-treatment and pre-dosing regimens, were included. Dosimetry was performed based on multiple SPECT/CT images. FDG PET/CT was performed at baseline and at 3 and 6 months. SUV$_{\text{max}}$, MTV, TLG, and changes in these parameters were calculated for each tumor. Lesion response was evaluated at 3 and 6 months (PET$_{3\text{months}}$ and PET$_{6\text{months}}$) based on Deauville criteria. Anatomical changes based on ceCT at baseline and at 6 and 12 months were investigated by the sum of perpendiculars (SPD).

Results Tumor-absorbed doses ranged from 35 to 859 cGy. Intra- and interpatient variations were observed. Mean decreases in PET parameters from baseline to 3 months were $\Delta$SUV$_{\text{max}3\text{months}}$ 61%, $\Delta$MTV$_{3\text{months}}$ 80%, and $\Delta$TLG$_{3\text{months}}$ 77%. There was no overall correlation between tumor-absorbed dose and change in FDG PET or ceCT parameters at the lesion level or significant difference in tumor-absorbed doses between metabolic responders and non-responders after treatment.

Conclusion Our analysis does not show any correlation between tumor-absorbed doses and changes in FDG PET or ceCT parameters for the included lesions. The combination regimen, including cold antibodies, may be one of the factors precluding such a correlation. Increased intra-patient response with increased tumor-absorbed doses was observed for most patients, implying individual variations in radiation sensitivity or biology.

Trial registration ClinicalTrials.gov Identifier (NCT01796171). Registered December 2012

Keywords Non-Hodgkin lymphoma · Radioimmunotherapy · $^{177}$Lu-lilotomab satetraxetan · Tumor dosimetry · FDG PET/CT

Introduction
Targeted therapy with radiolabeled antibodies offers the unique possibility of dosimetric studies to plan treatment and to determine absorbed dose after treatment which other pharmacological treatment modalities lacks. While non-Hodgkin lymphomas (NHL) are known to be highly radiosensitive [1], dose-effect relationships known from external beam radiation cannot be directly applied to targeted radiotherapy [2, 3]. Developing methods to accurately determine tumor-absorbed doses and establishing dose-effect correlations are therefore important for radioimmunotherapy (RIT) development. However, attempts in previous studies to show reliable
correlations between dosimetric evaluations and response after RIT in lymphoma have so far not been successful [4–7]. In the era of personalized precision medicine with development of highly advanced techniques, various metabolic and anatomical features have been made possible to measure. Thus new methods for dosimetry and imaging should be explored in this setting.

Two RITs have been approved by the US Food and Drug Administration: $^{131}$I-tositumomab (Bexxar®) and $^{90}$Y-ibritumomab tiuxetan (Zevalin®). Both agents consist of a monoclonal antibody specifically targeting the cell surface CD20 antigen, with a β-emitting radionuclide attached [8, 9]. Considering that these patients may be refractory to anti-CD20 monoclonal antibodies because of previous treatments, a conjugate that targets another B cell antigen, CD37 could be beneficial [10, 11]. Similar to CD20, CD37 is an antigen consistently expressed on the surface of B cells and B cell leukemia and lymphoma cells [10, 12, 13]. It is also found intracellularly at endosome and exosome level [14]. The B cell selectivity makes it a potentially valuable therapeutic target [10, 12, 13], and several CD37 reactive compounds have shown promise for treatment of NHL [12, 15–17]. Interestingly, preclinical studies have shown that the combined targeting of CD37 and CD20 with $^{177}$Lu-lilotomab satetraxetan and rituximab can improve the therapeutic outcome of NHL [18].

$^{177}$Lu-lilotomab satetraxetan or Betalutin® (Nordic Nanovector ASA, Oslo, Norway), which binds CD37, is a novel antibody-radionuclide conjugate for treatment of relapsed CD37+ indolent non-Hodgkin lymphoma which has been investigated in the first-in-human phase 1/2a study LYMRIT-37-01 [11]. Several regimens of pre-treatment with rituximab and pre-dosing with lilotomab (i.e., non-radioactive CD37 antibody) or rituximab and different activity levels of $^{177}$Lu-lilotomab satetraxetan were explored. We have already developed dosimetric methods to determine tumor-absorbed doses based on single photon emission tomography/computed tomography (SPECT/CT) data in this study [19]. $^{18}$F-fluorodeoxyglucose positron emission tomography/computed tomography ($^{18}$F-FDG PET/CT) (from here on referred to as FDG PET) and contrast enhanced computed tomography (ceCT) were performed to evaluate response to treatment with $^{177}$Lu-lilotomab satetraxetan.

The aim of the present study was to investigate lesion-based response in the phase 1 part of the phase 1/2a LYMRIT 37-01 trial, exploring the changes in different metabolic and anatomical parameters in correlation with tumor-absorbed dose. FDG PET was used to define metabolic changes by the measures of maximum standardized uptake value (SUV$_{\text{max}}$), metabolic tumor volume (MTV), total lesion glycolysis (TLG), and response according to a 5 point scale (Deauville criteria) in respective lesions at baseline and after 3 and 6 months. In addition, sum of perpendiculars measured by ceCT at baseline, 6 and 12 months was evaluated.

### Material and methods

#### Patient characteristics and treatment

A total of 16 patients with relapsed B cell indolent NHL treated at Oslo University Hospital were included in this study. All were part of the multicenter LYMRIT 37-01 phase 1/2a study, but only patients from this center, with lesions eligible for dosimetry, were included to assure image standardization. CD37 status of patients was histologically confirmed. Histological subtypes were follicular lymphoma grades I and II and mantle cell lymphoma. All but one had received several previous treatment regimens including rituximab (Table 1). The phase 1/2a LYMRIT-37-01 trial was approved by the regional ethical committee, and all patients had signed an informed consent form.

Different combinations of pre-treatment and pre-dosing regimens and three different dosage levels were tested in five arms. Patients received a single injection of $^{177}$Lu-lilotomab satetraxetan, either 10, 15, or 20 MBq/kg body weight. Before administration of $^{177}$Lu-lilotomab satetraxetan, all patients were pre-treated with rituximab (Fig. 1). In addition, patients in arm 1, 3, 4, and 5 received unlabeled antibody (lilotomab or rituximab) as pre-dosing 1–4 h before injection of $^{177}$Lu-lilotomab satetraxetan (Fig. 1).

#### FDG PET and ceCT imaging

FDG PET was performed at baseline (PET$_{\text{baseline}}$); within 2 weeks of the first pre-treatment. It was repeated 3 months (PET$_{\text{3months}}$) and 6 months (PET$_{\text{6months}}$) after $^{177}$Lu-lilotomab satetraxetan treatment (Fig. 2). PET/CT images were acquired using a Siemens Biograph 16 or a GE Discovery MI PET/CT scanner. Acquisition was performed from vertex to mid-thigh 57–81 min after intravenous administration of 267 to 412 MBq of FDG, 3–2.5 min/bed scan time. All PET scans were reconstructed to comply with the EARL standard. Baseline ceCT was performed within 2 weeks of the first pre-treatment and repeated at regular time points after $^{177}$Lu-lilotomab satetraxetan treatment (Fig. 2). Only ceCT examinations at baseline (CT$_{\text{baseline}}$), 6 months (CT$_{\text{6months}}$) and 12 months (CT$_{\text{12months}}$), were evaluated in the current work. Examples of lesions visualized on PET and ceCT are shown in Fig. 3. One patient did not undergo PET$_{\text{6months}}$, CT$_{\text{6months}}$, and CT$_{\text{12months}}$ because of disease progression and change of treatment. Same applies to three other patients regarding CT$_{\text{12months}}$.

#### PET quantification

For each lesion eligible for tumor dosimetry, and with uptake higher than maximum standardized uptake value (SUV$_{\text{max}}$) of liver at PET$_{\text{baseline}}$, SUV$_{\text{max}}$ and metabolic tumor volume
### Table 1  Patient characteristics

| Characteristic                              | Value             |
|--------------------------------------------|-------------------|
| Age (y), median (range)                    | 70 (38–88)        |
| Gender, n (%)                              | 11 (69%)/5 (31%)  |
| History, n (%)                             |                   |
| Follicular lymphoma, grade I               | 5 (31%)           |
| Follicular lymphoma, grade II              | 10 (63%)          |
| Mantle cell lymphoma                       | 1 (6%)            |
| Total injected activity, MBq               | 1229 (746–2189)   |
| Injected activity/body weight, n (%)       |                   |
| 10 MBq/kg                                  | 3 (19%)           |
| 15 MBq/kg                                  | 6 (38%)           |
| 20 MBq/kg                                  | 7 (44%)           |
| Pre-treatment, n (%)                       |                   |
| Rituximab 375 mg/m² 28 and 21 days before treatment (arms 1 and 2) | 8 (50%) |
| Rituximab 375 mg/m² 14 days before treatment (arms 3, 4, and 5) | 8 (50%) |
| Pre-dosing, n (%)                          |                   |
| Lilotomab 40 mg (arm 1)                    | 5 (31%)           |
| No pre-dosing (arm 2)                      | 3 (19%)           |
| Rituximab 100 mg/m² (arm 4)               | 5 (31%)           |
| Lilotomab 60 mg/m² (arm 5)                | 1 (6%)            |
| Number of tumors per patient, mod (range) | 3 (1–5)           |
| Number of previous treatments with rituximab, median (mod) (range) | 10 (8) (0–26) |

**Fig. 1** Study design: 3 different dosage levels, 10, 15, or 20 MBq/kg, were investigated in five arms of the phase 1/2a trial. Different pre-dosing regimens were given 1–3 h before ¹⁷⁷Lu-lilotomab satetraxetan injection, except for arm 2. Pre-treatment regimens were given 28 and 21 days or 14 days before. FDG PET and ecCT were performed as baseline investigations and for response evaluation. The 0-h time point on the grey time line indicates administration of ¹⁷⁷Lu-lilotomab satetraxetan.
(MTV) were measured, and total lesion glycolysis (TLG) was calculated at all PET time points, according to EANM procedure guidelines for tumor imaging: version 2 [20]. Syngo.via software solution (Siemens Healthineers) was used. A MTV threshold of 41% was applied. MTV and TLG at PET3months and PET6months were measured if uptakes were higher than liver uptake defined by PERCIST criteria [21]. Otherwise, they were registered as zero. SUVmax was registered as zero at PET3months and PET6months if the value was under blood background defined as in Deauville criteria [22]. Changes in FDG PET parameters in each lesion from PETbaseline to PET3months were calculated as percent reduction from baseline value: ΔSUVmax-3months, ΔMTV3months, and ΔTLG3months. Only SUVmax was used to measure metabolic change from PETbaseline to PET6months (ΔSUVmax-6months). All PET measurements and evaluations were performed by an experienced nuclear medicine physician.

Response assessment

Response at lesion level was assessed at PET3months according to Deauville criteria (5 point scale) [22]. Lesions were divided into 2 groups at PET3months: Deauville score 1, 2, and 3 defined as responders, PET3months (−), and Deauville score 4 and 5 defined as non-responders, PET3months (+). Uptake in lesions at PET6months was similarly interpreted as negative, PET6months (−), or positive, PET6months (+).

Size of lesions on ceCT was assessed according to Lugano criteria by the sum of perpendiculars (SPD) [23]. Change in size from baseline to 6 months (ΔCT6month) and from baseline to 6 months (ΔCT6month) for a patient 17, b patient 21, and c patient 16.
to 12 months ($\Delta \text{CT}_{12\text{months}}$) was calculated as percent reduction from baseline value.

Taking into account that rituximab given as pre-treatment may affect tumor volume before $^{177}$Lu lilotomab satetrazetan injection, a possible change in volume per lesion was defined. This was done by manual volume segmentation on the low-dose CT of the PET$_{\text{baseline}}$ examination and the low-dose CT at day 1 SPECT/CT in arms 2, 3, 4, and 5. This enabled us to isolate the possible rituximab effect (up until day 1) from the investigational $^{177}$Lu-lilotomab satetrazetan effect. Change in volume ($\Delta \text{CT}_{\text{ritux}}$) was calculated as percent reduction from baseline value.

**SPECT/CT imaging and dosimetry**

SPECT/CT scans were acquired with a Siemens Symbia T16 scanner at 96 and 168 h post-injection (p.i.) in arm 1 and at 24, 96, and 168 h p.i. in arms 2, 3, 4, and 5 (Fig. 2). The criteria for dosimetry to be performed included the ability to visually differentiate volume on low-dose CT and activity on SPECT, as well as a minimum volume of 1.5 mL. Two individual volume of interests (VOIs) were defined for each tumor, mass VOI delineated on low-dose CT and activity VOI delineated on SPECT, both drawn manually slice by slice by an experienced nuclear medicine specialist [19]. The masses derived from the CT VOIs were used for dose calculations, and the time activity curves based on uptake values at all time points were used to determine tumor-absorbed doses as described previously [19].

**Statistics**

Pearson correlation tests were performed to investigate relationship between tumor-absorbed dose and $\Delta \text{SUV}_{\text{max},3\text{months}}$, $\Delta \text{MTV}_{3\text{months}}$, $\Delta \text{TLG}_{3\text{months}}$, $\Delta \text{SUV}_{\text{max},6\text{months}}$, $\Delta \text{CT}_{6\text{months}}$, and $\Delta \text{CT}_{12\text{months}}$. Pearson correlation coefficient with a significance level of $p < 0.05$ was used. The box plots show median values, interquartile ranges, and points lower or higher than 1.5 times the lower or upper quartile displayed as outliers. The Mann–Whitney $U$ test was used to test differences in tumor-absorbed dose between response categories at PET$_{3\text{months}}$ and PET$_{6\text{months}}$. A null-hypothesis of equal populations with a rejection level of 0.05 was set. IBM SPSS statistics version 26 was used for all statistical analysis. GraphPad Prism 7 was used to create graphs.

**Results**

Sixteen patients had one or more tumors eligible for dosimetry and had undergone PET$_{\text{baseline}}$, PET$_{3\text{months}}$, and PET$_{6\text{months}}$. A total of 45 lesions were included for tumor dosimetry (1 to 5 lesions/patient). Tumor-absorbed doses ranged from 35 to 859 cGy (Table 2). Mean tumor-absorbed dose normalized for injected $^{177}$Lu-lilotomab satetrazetan was 2.3 mGy/MBq (range 0.4–6.7 mGy/MBq).

The mean baseline PET parameters for all lesions were $\text{SUV}_{\text{max},\text{baseline}}$ 9.7 (4.6–19.4), $\text{MTV}_{12\text{months}}$ 1.3 (0.1–7.8), and TLG 87.9 (7.6–1071.1). Mean tumor volume based on CT at day 4 SPECT was 14 mL (range 1.5–99.3 ml). An overview of the individual arms is given in Table 2. The mean reduction in PET parameters from baseline to 3 months were $\Delta \text{SUV}_{\text{max},3\text{months}}$ 61% (−60 to 100%), $\Delta \text{MTV}_{3\text{months}}$ 80% (−12 to 100%), and $\Delta \text{TLG}_{3\text{months}}$ 77% (−70 to 100%) (refer to Supplementary Table 1 for individual lesions). The mean reduction in $\Delta \text{SUV}_{\text{max},6\text{months}}$ was 56% (−62 to 100%). The mean $\Delta \text{CT}_{6\text{months}}$ was 35% (−41 to 72%), and $\Delta \text{CT}_{12\text{months}}$ was 33% (−41 to 78%).

There was no overall correlation neither between tumor-absorbed doses and $\Delta \text{SUV}_{\text{max},3\text{months}}$ ($r = 0.54$, $p = 0.73$), $\Delta \text{SUV}_{\text{max},6\text{months}}$ ($r = 0.11$, $p = 0.46$), $\Delta \text{MTV}_{3\text{months}}$ ($r = 0.02$, $p = 0.89$), and $\Delta \text{TLG}_{3\text{months}}$ ($r = 0.06$, $p = 0.66$) nor between tumor-absorbed doses and $\Delta \text{CT}_{6\text{months}}$ ($r = -0.10$, $p = 0.45$) and $\Delta \text{CT}_{12\text{months}}$ ($r = 0.53$, $p = 0.08$) (Fig. 4). The data set was also divided into 3 groups: Low lilotomab (arm 1), no lilotomab (arms 2 and 3), and high lilotomab (arms 4 and 5). Each group was analyzed separately, and no correlations between tumor-absorbed doses and $\Delta \text{SUV}_{\text{max,3months}}$ (low lilotomab $r = 0.37$, $p = 0.17$, no lilotomab $r = -0.21$, $p = 0.47$, high lilotomab $r = 0.07$, $p = 0.81$), $\Delta \text{SUV}_{\text{max,6months}}$ (low lilotomab $r = 0.45$, $p = 0.06$, no lilotomab $r = -0.37$, $p = 0.19$, high lilotomab $r = 0.17$, $p = 0.54$), $\Delta \text{MTV}_{3\text{months}}$ (low lilotomab $r = 0.25$, $p = 0.38$, no lilotomab $r = -0.06$, $p = 0.85$, high lilotomab $r = -0.22$, $p = 0.42$), and $\Delta \text{TLG}_{3\text{months}}$: (low lilotomab $r = 0.27$, $p = 0.33$, no lilotomab $r = -0.01$, $p = 0.98$, high lilotomab $r = -0.22$, $p = 0.41$) were found.

Thirty of 45 tumors (67%) had a metabolic response at PET$_{3\text{months}}$ according to the Deauville 5-point scale (Deauville 1, 2, and 3). Mean SUV$_{\text{max}}$ at PET$_{\text{baseline}}$ for responders was 9.2. Mean tumor volume was 9.8 mL. The mean reductions in FDG PET parameters for this group were $\Delta \text{SUV}_{\text{max,3months}}$ 91% (52%–100%), $\Delta \text{MTV}_{3\text{months}}$ 100%, and $\Delta \text{TLG}_{3\text{months}}$ 100%. Follow up with CT in this group showed mean reduction in SPD to be $\Delta \text{CT}_{6\text{months}}$ 47% (−9 to 72%) and $\Delta \text{CT}_{12\text{months}}$ 47% (−28 to 78%) (Supplementary Table 1).

Fifteen of 45 tumors (33%) were metabolic non-responders at PET$_{3\text{months}}$ based on the 5-point scale (Deauville 4 and 5). Mean SUV$_{\text{max}}$ at PET$_{\text{baseline}}$ was 10.4. Mean tumor volume was 16.8 mL. Mean reductions in FDG PET parameters for this group were $\Delta \text{SUV}_{\text{max,3months}}$ 0.6% (−60 to 66%), $\Delta \text{MTV}_{3\text{months}}$ 41% (−12 to 89%), and $\Delta \text{TLG}_{3\text{months}}$ 32% (−70 to 96%). Mean reductions in SPD were $\Delta \text{CT}_{6\text{months}}$ 10% (−41 to 54%) and mean $\Delta \text{CT}_{12\text{months}}$ 1.5% (−41 to 35%) (Supplementary Table 1).
There was no statistically significant difference in tumor-absorbed doses between responding and non-responding lesions at PET$_{3\text{months}}$ ($p = 0.22$) (Fig. 5a). Mean tumor-absorbed dose for responding lesions was 323 cGy (76–794 cGy), for non-responding lesions 313 cGy (35–859 cGy).

Metabolic response at PET$_{3\text{months}}$ was also evaluated according to 5-point scale. Twenty-six of 44 tumors (59%) had metabolic response, and 18 of 44 tumors (41%) were metabolic non-responders at PET 6 months. Although there was slightly higher tumor-absorbed doses in responders than in non-responders at PET$_{3\text{months}}$, this was not statistically significant ($p = 0.18$) (Fig. 5b). Mean absorbed dose for responding lesions was 342 cGy (76–794 cGy), while it was 291 cGy (35–859 cGy) for non-responding lesions.

Mean volume shrinkage per lesion in the interval from PET$_{\text{baseline}}$ to $^{177}$Lu-lilotomab satetraxetan injection, defined as ΔCT$_{\text{ritux}}$, was 8% (–28 to 40%) (Supplementary Table 1). There was no statistically significant difference in ΔCT$_{\text{ritux}}$ between arm 2 which received rituximab at 28 and 21 days before $^{177}$Lu-lilotomab satetraxetan and arms 3, 4, and 5 which received rituximab 14 days before ($p = 0.55$) (Fig. 1). Arm 3 was pooled with arms 4 and 5 as it is assumed that rituximab given as pre-dosing does not have any effect on tumor shrinkage as measured at CT the following day (day 1 SPECT/CT). No significant overall correlation was found between ΔCT$_{\text{ritux}}$ and ΔSUV$_{\text{max3months}}$ ($r = 0.32$, $p = 0.09$) at PET$_{3\text{months}}$. At PET$_{6\text{months}}$, there was a significant correlation between ΔCT$_{\text{ritux}}$ and ΔSUV$_{\text{max6months}}$ ($r = 0.45$, $p = 0.02$).

Neither baseline SUV$_{\text{max}}$ nor tumor volume (measured at the day 4 CT from the SPECT/CT scans) did show a correlation with tumor-absorbed dose ($r = -0.35$, $p = 0.82$ and $r = -0.15$, $p = 0.31$, respectively) (Fig. 6). Responding and non-responding lesions at PET$_{3\text{months}}$ did not show any statistically significant differences in tumor volume or SUV$_{\text{max}}$ at baseline ($p = 0.21$, $p = 0.24$, respectively) or at PET$_{6\text{months}}$ ($p = 0.96$, $p = 0.49$, respectively).

**Discussion**

Changes in FDG PET parameters after therapy with radiolabeled antibodies in correlation with tumor-absorbed doses have not been examined previously in patients with lymphoma. In this study, we tested different imaging parameters to evaluate response at the lesion level after $^{177}$Lu-lilotomab satetraxetan treatment and correlations with tumor-absorbed doses. No clear correlations were observed between the absorbed doses and the response based on imaging modalities and methods used.

NHL are known to be highly radiosensitive, and external beam radiotherapy (EBRT) is known to be very effective, and often curative in patients with localized disease [24]. Even low-dose radiation down to 4 Gy achieves high rates of local control [25]. However, current knowledge regarding absorbed dose-response relationships from EBRT cannot necessarily be directly applied to targeted radiotherapies [2]. Contrary to EBRT, targeted radiotherapies deliver continuous, generally low-dose rates, and often heterogeneous-absorbed doses to tissue. In the current study, large variations in tumor-absorbed doses were observed both intra-patient and within each study arm (Table 2), and the latter cannot be attributed only to different dosage levels (10–20 MBq/kg body weight). Tumor-absorbed doses in single lesions ranged from 35 to 859 cGy (median 330 cGy), and while the majority of lesions showed a metabolic response, no apparent overall dose-effect trend was observed (Fig. 4). The largest intra-patient variation found in our material was for patient 19, range 149–859 cGy (median 710 cGy) (Supplementary Table 1). Despite that the second highest mean absorbed dose was found in this patient, none of the four lesions responded at PET$_{3\text{months}}$ and PET$_{6\text{months}}$. The two other patients with the highest mean

### Table 2  Mean baseline PET parameters, tumor volume, tumor-absorbed dose, and tumor-absorbed dose/injected activity

| Arm | Number of lesions | Baseline PET parameters | Tumor volume (mL) | Tumor-absorbed dose [cGy] | Tumor-absorbed dose/injected activity [mGy/MBq] |
|-----|-------------------|-------------------------|------------------|--------------------------|-----------------------------------------------|
|     |                   | SUV$_{\text{max}}$ | MTV | TLG |                   |                                          |
| 1   | 15                | 9.3 (5.3–13.9) | 10.4 (2.1–21.3) | 63.8 (9.2–132.3) | 10.2 (1.5–25) | 303 (76–794) | 2.3 (0.5–5.3) |
| 2   | 8                 | 6.4 (4.6–12.1) | 9.9 (3.9–15.6) | 42.9 (12.2–92.9) | 10.0 (3.8–15.7) | 281 (123–728) | 2.3 (0.9–5.1) |
| 3   | 6                 | 9.1 (6.3–12.3) | 8.7 (1.9–26.6) | 61.0 (7.6–220.8) | 7.7 (1.7–20.4) | 183 (35–287) | 1.7 (0.4–2.7) |
| 4   | 11                | 12.2 (7.2–19.4) | 21.0 (2.6–112.8) | 180.0 (167–1071.0) | 28.4 (1.8–99.3) | 370 (149–859) | 2.6 (1.0–6.7) |
| 5   | 5                 | 11.6 (10.8–12.1) | 7.7 (4.9–9.7) | 54.8 (34.0–76.3) | 7.1 (3.5–10.2) | 482 (421–544) | 2.8 (2.4–3.7) |

Mean (range) values are given for each parameter.
absorbed doses (patients 17 and 25) showed complete metabolic response at PET 3months and PET 6months. Hence, there must be other factors that play important roles as discussed below, associated with the individual radiosensitivity in the current absorbed dose range. While no direct comparisons can be made, individual radiosensitivity is indicated by the occasionally observed responses for absorbed doses even less than the low-dose RT shown to be effective in NHL [25]. Furthermore, for the majority of cases, an improved response is observed for lesions receiving higher absorbed doses within individual patients (Fig. 7). Various gene products, as TP53, ATM, and NK-κB complexes, are known to be associated with radioresistance for lymphoma cells [26–30], and underlying gene mutations and expressions can potentially contribute to the interpatient variance in dose threshold needed for response. Correlating dosimetric results to efficacy measured by imaging modalities other than PET/CT has mostly been unsuccessful in previous studies of RIT in lymphoma [4–6].

Even though a larger data set of 124 lesions showed a significant correlation with response after 131I-tositumomab treatment; the $r$ value between tumor shrinkage and mean tumor-absorbed dose was modest [7]. The authors measured both activity and tumor volume on SPECT/CT data, probably resulting in measurements comparable with our results [7]. We found absorbed doses for $^{177}$Lu-lilotomab satetraxetan therapy in the same order of magnitude as the absorbed doses in the mentioned study by Dewaraja et al. However, they reported a much stronger dose-response correlation for $^{131}$I-tositumomab treatment when adjusting for other biological effects, such as cold antibodies. These corrections were made possible by the tracer prediction studies performed for $^{131}$I-tositumomab patients and are therefore not possible to replicate in the current study.

FDG PET in evaluating metabolic response in lymphomas is widely accepted as the preferred imaging tool [31–33]. Still, use of this modality in response evaluation has met some
skepticism for follicular lymphoma (FL)—contrary to Hodgkin lymphoma and diffuse large B cell lymphoma in the early PET era. Variations in glucose avidity of FL, response evaluation criteria with different thresholds, and use of older technology PET scanners may be have been contributing factors. However, a more recent study showed FDG PET as the most important factor predicting progression-free survival and overall survival after induction therapy for FL [34]. After the publication of the Lugano criteria, PET has become the standard imaging tool for staging, restaging, and response evaluation of lymphoma including FL [33]. We applied the widely accepted Deauville 5-point scale to categorize responders and non-responders [35, 36]. In our study, tumor-absorbed dose did not show significant overall correlation with change in FDG PET parameters. Interestingly, the difference in absorbed dose between responding and non-responding lesions became more apparent at PET_{6months} than at PET_{3months} (Fig. 5). Tumor-absorbed doses were slightly higher in responders than in non-responders at PET_{6months}, although the difference was not significant ($p = 0.18$). Inflammation is a side effect of radiation on tissues, and it is also a well-known pitfall that inflammatory changes in

---

Fig. 7 Tumor-absorbed doses plotted against $\Delta$SUV_{max,3months} in a arm 1, b arm 2, c arm 3, and d arms 4 + 5. In each panel, different color and symbol codings represent individual patients, and each symbol represents an individual tumor lesion. The lines represent correlation between $\Delta$SUV_{max,3months} and dose for tumors in individual patients. Interpatient variability in radiosensitivity is here evident, and intrapatient dose-response relationships also appear for most patients.
irradiated tissue give higher FDG uptakes. It is possible that effects of RIT may be masked at PET_{3months} because of inflammation and become apparent after 6 months when the post irradiation inflammatory reaction is presumably over [37]. However, no overall correlation between tumor-absorbed doses and reduction in ΔSUV_{max-6months} was found. Fan et al. suggested SUV_{max-liver} based response evaluation to exclude a possible inflammatory-enhancing effect on FDG uptake. The group suggested a threshold of 1.6 × SUV_{max-liver} for interim PET and 1.4 × SUV_{max-tumor} for end of treatment PET for better accuracy [35, 36]. In our cohort, this analysis failed to show any significant differences in tumor-absorbed doses between responders and non-responders at 3 months and 6 months (p = 0.9 and p = 0.64, respectively). Several studies found high false positive mid-therapy, response evaluation, and follow-up FDG PET studies in DLBCL patients receiving combination treatment with rituximab [38, 39]. This can be attributed to immune response activation, and according to Avivi et al., this effect may persist up to 3 years [38]. A meta-analysis by Sun et al. reported limited diagnostic accuracy of interim FDG PET with low-pooled sensitivity and specificity in NHL patients receiving R-CHOP (0.52 and 0.68, respectively) [40]. It is not unlikely that this inflammatory effect caused by immune response activation may mask treatment-related reduction in FDG uptake. To be consistent with previous investigations where volume derived from CT was used to assess response [5, 6], we also tested anatomical changes in ceCT from baseline to 6 and 12 months after therapy. No significant correlations with tumor-absorbed doses were found with this method neither.

Therapies with radionuclides linked to antibodies may also introduce immunological effects [3] that can be difficult to separate from radiobiological effects. Other factors than absorbed doses may therefore have influenced metabolic changes at FDG PET, like the pre-dosing and pre-treatment regimens tested (Fig. 1). From cell studies, the cell-killing effect of cold lilotomab appears to be limited [41], but the clinical translation is still to be determined. We have previously shown that pre-dosing with cold lilotomab results in lower absorbed doses to bone marrow and higher tumor-to-bone marrow absorbed dose ratios [42]. This demonstrates that the lilotomab pre-dosing alters biodistribution and probably renders more ^{177}Lu-lilotomab satetraxetan available for tumors. While higher ΔSUV_{max} values were observed in the pre-dosed group (arms 1, 4, and 5) than in the not pre-dosed group (arms 2 and 3) (PET_{3months} p = 0.12, PET_{6months} p = .006), variances in tumor exposure and activity dosage levels can explain the differences. No correlations between tumor-absorbed dose and ΔSUV_{max-3months}, ΔMTV_{3months}, or ΔTLG_{3months} were found for groups separated by the amount of pre-dosing. However, with the limited numbers in each group, we cannot exclude the possibility that absorbed dose-response correlations are masked by different pre-dosing in this study.

Effect of rituximab given as pre-treatment may be another factor influencing change in FDG PET parameters. To investigate this possible effect, we have calculated the change in tumor size from manually determined volumes at the CT of the baseline PET/CT to the CT of day 1 SPECT/CT after ^{177}Lu-lilotomab satetraxetan injection. Relatively large variations were observed (−28 to 40%), independent of whether patients had received one rituximab injection 14 days before or two injections 21 and 28 days before. Previous studies have showed that treatment failure with rituximab increases with the number of previous rituximab treatments [43]; however, no significant correlation was found between number of previous rituximab treatments and ΔCT_{ritux} in our study (r = −0.14, p = 0.47). These findings support that only limited volume shrinkage is likely to occur in the narrow time span of 2–4 weeks or that the results can be random since most of the included patients were heavily treated previously. Although a statistically significant correlation between the modest volume shrinkage caused by rituximab and ΔSUV_{max-6months} was observed, it is not plausible to assume that one or two CD20 antibody administrations would have had a long-lasting effect, especially since the 3 months data did not show any correlation.

In our study, neither baseline SUV_{max} nor initial tumor volume was correlated with tumor-absorbed dose (Fig. 6). Furthermore, there were no differences in baseline tumor volume or baseline SUV_{max} between responders and non-responders at PET_{3month} or PET_{6month}. These results are of important clinical interest, as they demonstrate that prediction of tumor-absorbed doses or response is not feasible based on the imaging methods currently used in this study or timing of these. Development of a PET tracer based on the lilotomab antibody, made humanized to avoid HAMA, could provide more promising opportunities for imaging-based prediction.

Conclusions

Overall dose-response relationship at the lesion level was not clearly demonstrated in this study of ^{177}Lu-lilotomab satetraxetan treatment. FDG PET was used to evaluate the treatment-induced metabolic changes in our study, but ceCT changes were also investigated. The lack of correlation is in agreement with most dose-response studies of other radiolabeled antibodies.
Baseline individual tumor volume and $\text{SUV}_{\text{max}}$ probably do not have any predictive value for tumor-absorbed doses or metabolic response at the level lesion. Factors like variability in pre-treatment, pre-dosing, activity level, CD37 expression, as well as timing of FDG PET may also have played a role. Interestingly, we observed an intra-patient increased reduction in $\Delta\text{SUV}_{\text{max}}$ with higher absorbed doses. We hypothesize that variations in inherent radiosensitivity between patients and even tumors within patients may be as important as tumor-absorbed dose and baseline imaging characteristics to predict outcome after RIT. Hence, further investigations of genetic alterations correlated with radiosensitivity and resistance is warranted in order to better understand which patients will benefit most from treatment with $^{177}$Lu-lilotomab satetraxetan and other RIT compounds.

**Supplementary Information** The online version contains supplementary material available at [https://doi.org/10.1007/s00259-020-05098-x](https://doi.org/10.1007/s00259-020-05098-x).

**Acknowledgments** We thank the personnel at the Nuclear Medicine department at Oslo University Hospital for technical assistance with the acquisitions. Stine Nygaard, study nurse at the Department of Oncology, is also greatly acknowledged.

**Authors' contributions** All authors contributed to design and draft of the manuscript. All authors read and approved the final manuscript.

**Funding** LYMRIT 37-01 study is sponsored by Nordic Nanovector ASA.

**Compliance with ethical standards**

**Conflict of interest** Arne Kolstad were both in part supported by grants from the Norwegian Cancer Society. Arne Kolstad is member of the Scientific Advisory Board of Nordic Nanovector ASA. Jostein Dahl is an employee and shareholder of Nordic Nanovector ASA. Ayca Løndalen has no conflict of interest. Johan Blakkisrud has no conflict of interest. Mona-Elisabeth Revheim has no conflict of interest. Ulf Erik Madsbu has no conflict of interest. Caroline Stokke has no conflict of interest.

**Ethical approval and informed consent** All procedures performed were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/).

**References**

1. Lowry L, Smith P, Qian W, Falk S, Benstead K, Illidge T, et al. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiother Oncol. 2011;100(1): 86–92. [https://doi.org/10.1016/j.radonc.2011.05.013](https://doi.org/10.1016/j.radonc.2011.05.013).
2. Pouget JP, Lozza C, Deshayes E, Boudousq V, Navarro–Teulon I. Introduction to radiobiology of targeted radionuclide therapy. Front Med (Lausanne). 2015;2:12. [https://doi.org/10.3389/fmed.2015.00012](https://doi.org/10.3389/fmed.2015.00012).
3. Pouget JP, Navarro–Teulon I, Bardies M, Chouin N, Cartgon G, Pelegrin A, et al. Clinical radioimmunotherapy—the role of radiobiology. Nat Rev Clin Oncol. 2011;8(12):720–34. [https://doi.org/10.1038/nrclinonc.2011.160](https://doi.org/10.1038/nrclinonc.2011.160).
4. Koral KF, Dewaraja Y, Li J, Lin Q, Regan DD, Zasadny KR, et al. Update on hybrid conjugate-view SPECT tumor dosimetry and response in 131I-tositumomab therapy of previously untreated lymphoma patients. J Nucl Med. 2003;44(3):457–64.
5. Sgouros G, Squeri S, Ballangrud AM, Kolbert KS, Teitcher JB, Panagreas KS, et al. Patient-specific, 3-dimensional dosimetry in non-Hodgkin’s lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response. J Nucl Med. 2003;44(2):260–8.
6. Dewaraja YK, Schipper MJ, Roberson PL, Wilderman SJ, Amro H, Regan DD, et al. 131I-tositumomab radioimmunotherapy: initial tumor dose-response results using 3-dimensional dosimetry including radiobiologic modeling. J Nucl Med. 2010;51(7):1155–62. [https://doi.org/10.2967/jnumed.110.075176](https://doi.org/10.2967/jnumed.110.075176).
7. Dewaraja YK, Schipper MJ, Shen J, Smith LB, Murgic J, Savas H, et al. Tumor-absorbed dose predicts progression-free survival following (131)I-tositumomab radioimmunotherapy. J Nucl Med. 2014;55(7):1047–53. [https://doi.org/10.2967/jnumed.113.136044](https://doi.org/10.2967/jnumed.113.136044).
8. Kaminski MS, Tuck M, Estes J, Kolstad A, Ross CW, Zasadny K, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005;352(5):441–9. [https://doi.org/10.1056/NEJMoa041511](https://doi.org/10.1056/NEJMoa041511).
9. Jacene HA, Filice R, Kasecampa W, Wahl RL. Comparison of 90Y-ibritumomab tuxetan and 131I-tositumomab in clinical practice. J Nucl Med. 2007;48(11):1767–76. [https://doi.org/10.2967/jnumed.107.043489](https://doi.org/10.2967/jnumed.107.043489).
10. Dahlé J, Repetto-Llamazares AH, Mollatt CS, Melhus KB, Bruland OS, Kolstad A, et al. Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin’s lymphoma. Anticancer Res. 2013;33(1):85–95.
11. Kolstad A, Illidge T, Bolstad N, Speitalen S, Madsbu I, Stokke C, et al. Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma. Blood Adv. 2020;4(17):4091–101. [https://doi.org/10.1182/bloodadvances.2020002583](https://doi.org/10.1182/bloodadvances.2020002583).
12. Zhao X, Lapalombella R, Joshi T, Cheney C, Gowda A, Hayden-Ledbetter MS, et al. Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical. Blood. 2007;110(7):2569–77. [https://doi.org/10.1182/blood-2006-12-062927](https://doi.org/10.1182/blood-2006-12-062927).
13. Schwartz-Albiez R, Dorken B, Hofmann W, M Henderson G. The B Cell-associated CD37 antigen (gp40-52). Structure and subcellular expression of an extensively glycosylated glycoprotein. J Immunol. 1988;140(3):905–14.
14. Bertoni F, Stathis A. Staining the target: CD37 expression in lymphomas. Blood. 2016;128(26):3022–3. [https://doi.org/10.1182/blood-2016-11-748137](https://doi.org/10.1182/blood-2016-11-748137).
15. Kaminski MS, Zasadny KR, Francis IR, Fenner MC, Ross CW, Milik AW, et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol. 1996;14(7):1974–81. https://doi.org/10.1002/JCO.1996.14.7.1974.

16. Heider KH, Kiefer K, Zenz T, Volden M, Stilgenbauer S, Ostermann E, et al. A novel fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies. Blood. 2011;118(15):4159–68. https://doi.org/10.1182/blood-2011-04-351932.

17. Deckert J, Park PU, Chicklas S, Yi Y, Li M, Lai KC, et al. A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies. Blood. 2013;122(20):3500–10. https://doi.org/10.1182/blood-2013-05-505685.

18. Repetto-Llamazares AHV, Malenge MM, O'Shea A, Eiriksdottir B, Stokke T, Larsen RH, et al. Combination of (177) Lu-lilotomab with rituximab significantly improves the therapeutic outcome in pre-clinical models of non-Hodgkin’s lymphoma. Eur J Haematol. 2018. https://doi.org/10.1111/ejh.13139.

19. Blakksrud J, Londalen A, Martinsen AC, Dahle J, Holtedahl JE, Bach-Gansmo T, et al. Tumor-absorbed dose for non-Hodgkin lymphoma patients treated with the anti-CD37 antibody radiolabeled with 177Lu-lilotomab ataxetaran. J Nucl. 2017;58(1):48–54. https://doi.org/10.2967/jnumed.116.173922.

20. Boelgaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Imaging. 2015;42(2):328–54. https://doi.org/10.1007/s00259-014-2961-x.

21. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):122S–50S. https://doi.org/10.2967/jnumed.108.057307.

22. Meignan M, Gallamini A, Meignan M, Gallamini A, Haioun C, et al. Report on the first international workshop on interim-PET-scan in lymphoma. Leuk Lymphoma. 2009;50(8):1257–60. https://doi.org/10.1080/1042819090340048.

23. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–68. https://doi.org/10.1200/JCO.2013.54.8800.

24. Barzenje DA, Civanicarova Smastuen M, Liestol K, Fossa S, Delabie J, Kolstad A, et al. Radiotherapy compared to other strategies in the treatment of stage I/II follicular lymphoma: a study of PRIMA trial participants. J Clin Oncol. 2011;29(23):2194–200. https://doi.org/10.1200/JCO.2011.35.0736.

25. Haas RL. Low dose radiotherapy in indolent lymphomas, enough is enough. Hematol Oncol. 2009;27(2):71–81. https://doi.org/10.1002/hon.882.

26. Wang YV, Leblanc M, Wade M, Jochemsen AG, Wahl GM. Increased radiosensitivity and accelerated B cell lymphomas in mice with Mdmx mutations that prevent modifications by DNA-damage-activated kinases. Cancer Cell. 2009;16(1):33–43. https://doi.org/10.1016/j.ccr.2009.05.008.

27. Novarski R, Wilner OI, Cheshin O, Shahar OD, Kenig E, Baraz L, et al. APOBEC3G enhances lymphoma cell radiosensitivity by promoting cytidine deaminase-dependent DNA repair. Blood. 2012;120(2):366–75. https://doi.org/10.1182/blood-2012-01-402123.

28. Li Q, Xu X, Zhong W, Du Q, Yu B, Xiong H. IL-17 induces radiation resistance of B lymphoma cells by suppressing p53 expression and thereby inhibiting irradiation-triggered apoptosis. Cell Mol Immunol. 2015;12(3):366–72. https://doi.org/10.1038/cmi.2014.122.

29. O’Connor PM, Jackman J, Jondle D, Bhatia K, Magrath I, Kohn KW. Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt’s lymphoma cell lines. Cancer Res. 1993;53(20):4776–80.

30. Zand H, Rahimipour A, Salimi S, Shafiei SM. Docosahexaenoic acid sensitizes Ramos cells to gamma-irradiation-induced apoptosis through involvement of PPAR-gamma activation and NF-kappaB suppression. Mol Cell Biochem. 2008;317(1–2):113–20. https://doi.org/10.1007/s11008-009-9838-x.

31. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–86. https://doi.org/10.1200/JCO.2006.09.2403.

32. Moghbil MC, Mittra E, Gallamini A, Niederkohr R, Chen DL, Zukotynski K, et al. Response assessment criteria and their applications in lymphoma: part 2. J Nucl Med. 2017;58(1):13–22. https://doi.org/10.2967/jnumed.116.184242.

33. Barrington SF, Mikhael NG, Kostakoglu L, Meignan M, Hutchings M, Mueller SP, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group. J Clin Oncol. 2014;32(27):3048–58. https://doi.org/10.1200/JCO.2013.53.5229.

34. Trotman J, Fournier M, Lamy T, Seymour JF, Sonet A, Janikova A, et al. Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants. J Clin Oncol. 2011;29(23):2194–200. https://doi.org/10.1200/JCO.2011.35.0736.

35. Fan Y, Zhang Y, Yang Z, Ying Z, Zhou N, Liu C, et al. Evaluating early interim fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography with the SUVmax-liver-based interpretation for predicting the outcome in diffuse large B-cell lymphoma. Leuk Lymphoma. 2017;58(9):1139–45. https://doi.org/10.1080/10428194.2016.1277384.

36. Zhang Y, Fan Y, Ying Z, Song Y, Zou N, Liu C, et al. Can the SUVmax/liver-based interpretation improve prognostic accuracy of interim and posttreatment (18)F-FDG PET/CT in patients with diffuse large B-cell lymphoma? J Nucl Med. 2017;58(9):1–9. https://doi.org/10.2967/jnumed.1016.155376.

37. Avivi I, Zilberlicht A, Dann EJ, Leiba R, Faibish T, Rowe JM, et al. Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era. Am J Hematol. 2013;88(5):400–5. https://doi.org/10.1002/ajh.23423.

38. Han HS, Escalon MP, Hsiao B, Serafini A, Lossos IS. High incidence of false-positive PET scans in patients with aggressive non-Hodgkin’s lymphoma treated with rituximab-containing regimens. Ann Oncol. 2009;20(2):309–18. https://doi.org/10.1093/annonc/mdn629.

39. Sun N, Zhao J, Qiao W, Wang T. Predictive value of interim PET/CT in DLBCL treated with R-CHOP: meta-analysis. Biomed Res Int. 2015;2015:648572. https://doi.org/10.1155/2015/648572.

40. Marcattil S, Pichard A, Couteau A, Ladjoohnouli R, Navarro-Teulon I, Repetto-Llamazares A, et al. Realistic multi-cellular
dosimetry for (177)Lu-labelled antibodies: model and application. Phys Med Biol. 2016;61(19):6935–52. https://doi.org/10.1088/0031-9155/61/19/6935.

42. Stokke C, Blakkisrud J, Londalen A, Dahle J, Martinsen ACT, Holte H, et al. Pre-dosing with lilotomab prior to therapy with (177)Lu-lilotomab satetrexetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients. Eur J Nucl Med Mol Imaging. 2018. https://doi.org/10.1007/s00259-018-3964-9.

43. Chao MP. Treatment challenges in the management of relapsed or refractory non-Hodgkin’s lymphoma - novel and emerging therapies. Cancer Manag Res. 2013;5:251–69. https://doi.org/10.2147/CMAR.S34273.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.